Статті в журналах з теми "Warfarin dosage"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Warfarin dosage".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
Lala, Mallika, Gilbert J. Burckart, Cheryl M. Takao, Vera Pravica, Jeremiah D. Momper, and Jogarao V. S. Gobburu. "Genetics-Based Pediatric Warfarin Dosage Regimen Derived Using Pharmacometric Bridging." Journal of Pediatric Pharmacology and Therapeutics 18, no. 3 (September 1, 2013): 209–19. http://dx.doi.org/10.5863/1551-6776-18.3.209.
Повний текст джерелаRecker, Mark W., and Karen L. Kier. "Potential Interaction between Clarithromycin and Warfarin." Annals of Pharmacotherapy 31, no. 9 (September 1997): 996–98. http://dx.doi.org/10.1177/106002809703100907.
Повний текст джерелаZatuchni, Jacob. "Guidelines for Warfarin Dosage." Drug Intelligence & Clinical Pharmacy 22, no. 10 (October 1988): 825–26. http://dx.doi.org/10.1177/106002808802201022.
Повний текст джерелаLiu, Hong-Qiang, Chang-Po Zhang, Chang-Zhen Zhang, Xiang-Chen Liu, and Zun-Jing Liu. "Influence of Two Common Polymorphisms in theEPHX1Gene on Warfarin Maintenance Dosage: A Meta-Analysis." BioMed Research International 2015 (2015): 1–12. http://dx.doi.org/10.1155/2015/564149.
Повний текст джерелаKim, Karissa Y., and Michael A. Mancano. "Fenofibrate Potentiates Warfarin Effects." Annals of Pharmacotherapy 37, no. 2 (February 2003): 212–15. http://dx.doi.org/10.1177/106002800303700210.
Повний текст джерелаDang, Mai-Trang N., Julie Hambleton, and Steven R. Kayser. "The Influence of Ethnicity on Warfarin Dosage Requirement." Annals of Pharmacotherapy 39, no. 6 (June 2005): 1008–12. http://dx.doi.org/10.1345/aph.1e566.
Повний текст джерелаMüller, C. R., S. Rost, M. Watzka, C. G. Bevans, and J. Oldenburg. "Comparative genetics of warfarin resistance." Hämostaseologie 34, no. 02 (2014): 143–59. http://dx.doi.org/10.5482/hamo-13-09-0047.
Повний текст джерелаAbsher, Randall K., M. Elisabeth Moore, and Mary H. Parker. "Patient-Specific Factors Predictive of Warfarin Dosage Requirements." Annals of Pharmacotherapy 36, no. 10 (October 2002): 1512–17. http://dx.doi.org/10.1345/aph.1c025.
Повний текст джерелаZhu, Yusheng, Michael Shennan, Kristen K. Reynolds, Nancy A. Johnson, Matthew R. Herrnberger, Roland Valdes, and Mark W. Linder. "Estimation of Warfarin Maintenance Dose Based on VKORC1 (−1639 G>A) and CYP2C9 Genotypes." Clinical Chemistry 53, no. 7 (July 1, 2007): 1199–205. http://dx.doi.org/10.1373/clinchem.2006.078139.
Повний текст джерелаEdwards, Clive, Timothy Butler, Hilary Wynne, and Farhad Kamali. "The Influence of (R)- and (S)-Warfarin, Vitamin K and Vitamin K Epoxide upon Warfarin Anticoagulation." Thrombosis and Haemostasis 84, no. 07 (2000): 39–42. http://dx.doi.org/10.1055/s-0037-1613964.
Повний текст джерела박선미, 인용원, 이영미, and 민경아. "Proposal for Warfarin Dosage Guideline during Warfarin-Propafenone Combination Therapy." Journal of Korean Society of Health-System Pharmacists 30, no. 1 (February 2013): 52–63. http://dx.doi.org/10.32429/jkshp.2013.30.1.005.
Повний текст джерелаLi, Shuang, Shixuan Liu, Xiaoran Roger Liu, Mengru Mira Zhang, and Weikai Li. "Competitive tight-binding inhibition of VKORC1 underlies warfarin dosage variation and antidotal efficacy." Blood Advances 4, no. 10 (May 20, 2020): 2202–12. http://dx.doi.org/10.1182/bloodadvances.2020001750.
Повний текст джерелаThompson, Dennis F., Marsha A. Raebel, Elizabeth K. Hussey, and George E. Dukes. "Do All Histamine2-Antagonists Cause a Warfarin Drug Interaction?" DICP 23, no. 9 (September 1989): 675–79. http://dx.doi.org/10.1177/106002808902300911.
Повний текст джерелаTrilli, Lauren E., Catherine L. Kelley, Sherrie L. Aspinall, and Beverly A. Kroner. "Potential Interaction between Warfarin and Fluvastatin." Annals of Pharmacotherapy 30, no. 12 (December 1996): 1399–402. http://dx.doi.org/10.1177/106002809603001207.
Повний текст джерелаMurphey, Lisa M., and Elizabeth H. Hood. "Bosentan and Warfarin Interaction." Annals of Pharmacotherapy 37, no. 7-8 (July 2003): 1028–31. http://dx.doi.org/10.1345/aph.1c398.
Повний текст джерелаDalere, Gloriann M., Robert W. Coleman, and Bert L. Lum. "A Graphic Nomogram for Warfarin Dosage Adjustment." Pharmacotherapy 19, no. 4 (April 1999): 461–67. http://dx.doi.org/10.1592/phco.19.6.461.31038.
Повний текст джерелаCheng, Tsung O. "Chinese patients require lower dosage of warfarin." International Journal of Cardiology 139, no. 1 (February 2010): 1. http://dx.doi.org/10.1016/j.ijcard.2009.06.056.
Повний текст джерелаStreif, W., M. Andrew, V. Marzinotto, P. Massicotte, A. K. C. Chan, J. A. Julian, and L. Mitchell. "Analysis of Warfarin Therapy in Pediatric Patients: A Prospective Cohort Study of 319 Patients." Blood 94, no. 9 (November 1, 1999): 3007–14. http://dx.doi.org/10.1182/blood.v94.9.3007.
Повний текст джерелаStreif, W., M. Andrew, V. Marzinotto, P. Massicotte, A. K. C. Chan, J. A. Julian, and L. Mitchell. "Analysis of Warfarin Therapy in Pediatric Patients: A Prospective Cohort Study of 319 Patients." Blood 94, no. 9 (November 1, 1999): 3007–14. http://dx.doi.org/10.1182/blood.v94.9.3007.421k09_3007_3014.
Повний текст джерелаZhao, Li, Jin Wang, Shaoxin Shi, Yuan Wu, Jumei Liu, Shiwei He, Yue Zou, Huabin Xie, Shengxiang Ge, and Huiming Ye. "Plasma miRNA profiles associated with stable warfarin dosage in Chinese patients." PeerJ 8 (October 13, 2020): e9995. http://dx.doi.org/10.7717/peerj.9995.
Повний текст джерелаJackevicius, Cynthia A., and Mannhu N. Ton. "Enhanced Interaction between Warfarin and High-Dose Ketoconazole: A Case Report." Case Reports in Medicine 2009 (2009): 1–3. http://dx.doi.org/10.1155/2009/315687.
Повний текст джерелаMason, Barb J. "Anticoagulant Clinic Warfarin Adherence Rates and Assessment." Journal of Pharmacy Technology 12, no. 3 (May 1996): 97–101. http://dx.doi.org/10.1177/875512259601200307.
Повний текст джерела최슬기, kieho sohn, 인용원, 민경아, and 전명훈. "Proposal for Warfarin Dosage Guideline during Capecitabine Therapy." Journal of Korean Society of Health-System Pharmacists 27, no. 3 (September 2010): 293–304. http://dx.doi.org/10.32429/jkshp.2010.27.3.003.
Повний текст джерелаCarter, Barry L., William Barr, William Rock, and Jerry W. Taylor. "Warfarin Dosage Predictions Assisted by the Analog Computer." Therapeutic Drug Monitoring 10, no. 1 (March 1988): 69–73. http://dx.doi.org/10.1097/00007691-198801000-00012.
Повний текст джерелаCarter, Barry L., William Barr, William Rock, and Jerry W. Taylor. "Warfarin Dosage Predictions Assisted by the Analog Computer." Therapeutic Drug Monitoring 10, no. 1 (1988): 69–73. http://dx.doi.org/10.1097/00007691-198810010-00012.
Повний текст джерелаHirsh, J. "Inadequate monitoring of warfarin dosage [letter] [see comments]." Blood 80, no. 2 (July 15, 1992): 562–63. http://dx.doi.org/10.1182/blood.v80.2.562.562.
Повний текст джерелаHirsh, J. "Inadequate monitoring of warfarin dosage [letter] [see comments]." Blood 80, no. 2 (July 15, 1992): 562–63. http://dx.doi.org/10.1182/blood.v80.2.562.bloodjournal802562.
Повний текст джерелаChen, Jin-Jer. "S28-4 WARFARIN DOSAGE REQUIREMENT BASED ON PHARMACOGENETICS." International Journal of Cardiology 122 (December 2007): S23. http://dx.doi.org/10.1016/s0167-5273(08)70381-4.
Повний текст джерелаSaleh, Mohammad I., and Sameh Alzubiedi. "Dosage Individualization of Warfarin Using Artificial Neural Networks." Molecular Diagnosis & Therapy 18, no. 3 (February 27, 2014): 371–79. http://dx.doi.org/10.1007/s40291-014-0090-7.
Повний текст джерелаLi, Siyue, Yuangao Zou, Xia Wang, Xunbei Huang, Yong Sun, Yuqing Wang, Li Dong, and Hong Jiang. "Warfarin Dosage Response Related Pharmacogenetics in Chinese Population." PLOS ONE 10, no. 1 (January 16, 2015): e0116463. http://dx.doi.org/10.1371/journal.pone.0116463.
Повний текст джерелаLastória, Sidnei, Arcangelo T. Fortes Jr, Francisco H. Abreu Maffei, Marcone Lima Sobreira, Hamilton A. Rollo, Regina Moura, and Winston Bonetti Yoshida. "Comparison of initial loading doses of 5 mg and 10 mg for warfarin therapy." Jornal Vascular Brasileiro 13, no. 1 (March 2014): 12–17. http://dx.doi.org/10.1590/jvb.2014.004.
Повний текст джерелаTian, Lihong, Pingping Xiao, Bingrong Zhou, Yishan Chen, Lijuan Kang, Qingqing Wang, Jianfeng Lin, Min Son, and Qingxiu Wu. "Influence of NQO1 Polymorphisms on Warfarin Maintenance Dose: A Systematic Review and Meta-Analysis (rs1800566 and rs10517)." Cardiovascular Therapeutics 2021 (August 12, 2021): 1–9. http://dx.doi.org/10.1155/2021/5534946.
Повний текст джерелаYoshida, Winston Bonetti, Regina Paolucci El Dib, Ricardo de Alvarenga Yoshida, and Francisco Humberto de Abreu Maffei. "Ximelagatran versus warfarin for prophylaxis of venous thromboembolism in major orthopedic surgery: systematic review of randomized controlled trials." Sao Paulo Medical Journal 124, no. 6 (November 2006): 355–61. http://dx.doi.org/10.1590/s1516-31802006000600012.
Повний текст джерелаHe, Shiwei, Yuan Wu, Shuidi Yan, Jumei Liu, Li Zhao, Huabin Xie, Shengxiang Ge, and Huiming Ye. "Methylation of CYP1A1 and VKORC1 promoter associated with stable dosage of warfarin in Chinese patients." PeerJ 9 (June 22, 2021): e11549. http://dx.doi.org/10.7717/peerj.11549.
Повний текст джерелаSoma-Pillay, P., Z. Nene, T. M. Mathivha, and A. P. Macdonald. "The effect of warfarin dosage on maternal and fetal outcomes in pregnant women with prosthetic heart valves." Obstetric Medicine 4, no. 1 (March 2011): 24–27. http://dx.doi.org/10.1258/om.2010.100067.
Повний текст джерелаShen, Guomin, Hao Zhang, Weidong Cui, Evan Sadler, Michael Gross, and Weikai Li. "Warfarin Inhibits Vitamin K Epoxide Reductase By Specifically Blocking at a Conformational and Redox State." Blood 124, no. 21 (December 6, 2014): 4214. http://dx.doi.org/10.1182/blood.v124.21.4214.4214.
Повний текст джерелаParrett, J. L., A. B. Reaves, T. H. Self, and R. E. Owens. "Enzalutamide‐warfarin interaction necessitating warfarin dosage adjustment: A case report of successful clinical management." Journal of Clinical Pharmacy and Therapeutics 43, no. 2 (September 12, 2017): 276–79. http://dx.doi.org/10.1111/jcpt.12612.
Повний текст джерелаZotova, I. V., A. G. Nikitin, E. N. Fattakhova, A. N. Brovkin, D. S. Khodyrev, E. Y. Lavrikova, M. Y. Isaeva, A. S. Kosukhina, V. V. Nosikov, and D. A. Zateyshchikov. "THE AFFECT OF INFLUENCE OF GENES' POLYMORPHISMS CYP2C9 AND VKORC1ON THE SAFETY OF THE THERAPY BY WARFARIN." Journal of Clinical Practice 4, no. 4 (December 15, 2013): 3–10. http://dx.doi.org/10.17816/clinpract443-10.
Повний текст джерелаBurkova, T. V., and I. A. Goncharova. "GENETIC FACTORS INFLUENCING THE EFFECTIVENESS AND SAFETY OF LONG-TERM ANTICOAGULANT THERAPY." Cardiovascular Therapy and Prevention 12, no. 3 (June 20, 2013): 89–94. http://dx.doi.org/10.15829/1728-8800-2013-3-89-94.
Повний текст джерелаJohn, Sumi Elsa, Dinu Antony, Muthukrishnan Eaaswarkhanth, Prashantha Hebbar, Fadi Alkayal, Jaakko Tuomilehto, Osama Alsmadi, and Thangavel Alphonse Thanaraj. "Genetic variants associated with warfarin dosage in Kuwaiti population." Pharmacogenomics 18, no. 8 (June 2017): 757–64. http://dx.doi.org/10.2217/pgs-2017-0020.
Повний текст джерелаLindh, Jonatan D. "Comment: Patient-Specific Factors Predictive of Warfarin Dosage Requirements." Annals of Pharmacotherapy 37, no. 3 (March 2003): 454. http://dx.doi.org/10.1345/aph.1c025a.
Повний текст джерелаREDWOOD, M., CLARE TAYLOR, BARBARA J. BAIN, and J. H. MATTHEWS. "The Association of Age with Dosage Requirement for Warfarin." Age and Ageing 20, no. 3 (1991): 217–20. http://dx.doi.org/10.1093/ageing/20.3.217.
Повний текст джерелаBrooks, Cath, Jane M. Rutherford, Jane Gould, Margaret M. Ramsay, and David K. James. "Warfarin dosage in postpartum women: a case-control study." BJOG: An International Journal of Obstetrics and Gynaecology 109, no. 2 (February 2002): 187–90. http://dx.doi.org/10.1111/j.1471-0528.2002.00490.x.
Повний текст джерелаBrooks, C. "Warfarin dosage in postpartum women: a case–control study." BJOG: An International Journal of Obstetrics and Gynaecology 109, no. 2 (February 2002): 187–90. http://dx.doi.org/10.1016/s1470-0328(02)00490-1.
Повний текст джерелаDimberg, Ivar, Bartosz Grzymala-Lubanski, Anette Hägerfelth, Mårten Rosenqvist, Peter Svensson, and Anders Själander. "Computerised assistance for warfarin dosage — Effects on treatment quality." European Journal of Internal Medicine 23, no. 8 (December 2012): 742–44. http://dx.doi.org/10.1016/j.ejim.2012.07.011.
Повний текст джерелаBrooks, Cath, Jane M. Rutherford, Jane Gould, Margaret M. Ramsay, and David K. James. "Warfarin Dosage in Postpartum Women: A Case-Control Study." Obstetrical & Gynecological Survey 57, no. 8 (August 2002): 491–92. http://dx.doi.org/10.1097/00006254-200208000-00007.
Повний текст джерелаRumyantsev, N. A., D. A. Sychev, V. G. Kukes, R. E. Kazakov, A. A. Rumyantsev, and T. V. Taratuta. "Experience of individualization of oral anticoagulants use and dosage in personalized medicine centre conditions." Kazan medical journal 96, no. 6 (December 15, 2015): 1065–68. http://dx.doi.org/10.17750/kmj2015-1065.
Повний текст джерелаDavis, David A., and Susan E. Fugate. "Increasing Warfarin Dosage Reductions Associated with Concurrent Warfarin and Repeated Cycles of 5-Fluorouracil Therapy." Pharmacotherapy 25, no. 3 (March 2005): 442–47. http://dx.doi.org/10.1592/phco.25.3.442.61598.
Повний текст джерелаPiovella, Franco, Marisa Barone, Chiara Beltrametti, Chiara Piovella, Andrea M. D’Armini, Federico Capra Marzani, Vittorio Arici, et al. "Efficacy of Fondaparinux in the Treatment of Heparin-Induced Thrombocytopenia with Venous Thromboembolism: Reduction of Thromboembolic Burden, Normalization of Platelet Count and Disappearance of Anti-Platelet Factor 4/Heparin Antibodies." Blood 108, no. 11 (November 16, 2006): 575. http://dx.doi.org/10.1182/blood.v108.11.575.575.
Повний текст джерелаDiener, H. C., and S. H. Hohnloser. "Dabigatran for stroke prevention in atrial fibrillation." Hämostaseologie 32, no. 03 (2012): 216–20. http://dx.doi.org/10.5482/ha-1196.
Повний текст джерела